227 related articles for article (PubMed ID: 23571544)
1. Pharmacokinetics and pharmacodynamics of fluconazole for cryptococcal meningoencephalitis: implications for antifungal therapy and in vitro susceptibility breakpoints.
Sudan A; Livermore J; Howard SJ; Al-Nakeeb Z; Sharp A; Goodwin J; Gregson L; Warn PA; Felton TW; Perfect JR; Harrison TS; Hope WW
Antimicrob Agents Chemother; 2013 Jun; 57(6):2793-800. PubMed ID: 23571544
[TBL] [Abstract][Full Text] [Related]
2. Fluconazole Monotherapy Is a Suboptimal Option for Initial Treatment of Cryptococcal Meningitis Because of Emergence of Resistance.
Hope W; Stone NRH; Johnson A; McEntee L; Farrington N; Santoro-Castelazo A; Liu X; Lucaci A; Hughes M; Oliver JD; Giamberardino C; Mfinanga S; Harrison TS; Perfect JR; Bicanic T
mBio; 2019 Dec; 10(6):. PubMed ID: 31796539
[TBL] [Abstract][Full Text] [Related]
3. Repurposing and Reformulation of the Antiparasitic Agent Flubendazole for Treatment of Cryptococcal Meningoencephalitis, a Neglected Fungal Disease.
Nixon GL; McEntee L; Johnson A; Farrington N; Whalley S; Livermore J; Natal C; Washbourn G; Bibby J; Berry N; Lestner J; Truong M; Owen A; Lalloo D; Charles I; Hope W
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29311092
[TBL] [Abstract][Full Text] [Related]
4. Experimental Models of Short Courses of Liposomal Amphotericin B for Induction Therapy for Cryptococcal Meningitis.
Lestner J; McEntee L; Johnson A; Livermore J; Whalley S; Schwartz J; Perfect JR; Harrison T; Hope W
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28320715
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamics of Isavuconazole in a Rabbit Model of Cryptococcal Meningoencephalitis.
Kovanda LL; Giamberardino C; McEntee L; Toffaletti DL; Franke KS; Bartuska A; Smilnak G; de Castro GC; Ripple K; Hope WW; Perfect JR
Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31209006
[No Abstract] [Full Text] [Related]
6. Population Pharmacokinetics and Cerebrospinal Fluid Penetration of Fluconazole in Adults with Cryptococcal Meningitis.
Stott KE; Beardsley J; Kolamunnage-Dona R; Castelazo AS; Kibengo FM; Mai NTH; Tùng NLN; Cuc NTK; Day J; Hope W
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914943
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamics of liposomal amphotericin B and flucytosine for cryptococcal meningoencephalitis: safe and effective regimens for immunocompromised patients.
O'Connor L; Livermore J; Sharp AD; Goodwin J; Gregson L; Howard SJ; Felton TW; Schwartz JA; Neely MN; Harrison TS; Perfect JR; Hope WW
J Infect Dis; 2013 Jul; 208(2):351-61. PubMed ID: 23599314
[TBL] [Abstract][Full Text] [Related]
8. Limited activity of miltefosine in murine models of cryptococcal meningoencephalitis and disseminated cryptococcosis.
Wiederhold NP; Najvar LK; Bocanegra R; Kirkpatrick WR; Sorrell TC; Patterson TF
Antimicrob Agents Chemother; 2013 Feb; 57(2):745-50. PubMed ID: 23165465
[TBL] [Abstract][Full Text] [Related]
9. Molecular epidemiology and antifungal susceptibility of Cryptococcus neoformans isolates from Ugandan AIDS patients.
Pfaller M; Zhang J; Messer S; Tumberland M; Mbidde E; Jessup C; Ghannoum M
Diagn Microbiol Infect Dis; 1998 Nov; 32(3):191-9. PubMed ID: 9884835
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy with fluconazole and flucytosine in the murine model of cryptococcal meningitis.
Nguyen MH; Najvar LK; Yu CY; Graybill JR
Antimicrob Agents Chemother; 1997 May; 41(5):1120-3. PubMed ID: 9145879
[TBL] [Abstract][Full Text] [Related]
11. Correspondence of in vitro and in vivo fluconazole dose-response curves for Cryptococcus neoformans.
Larsen RA; Bauer M; Thomas AM; Sanchez A; Citron D; Rathbun M; Harrison TS
Antimicrob Agents Chemother; 2005 Aug; 49(8):3297-301. PubMed ID: 16048939
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans.
Perfect JR; Cox GM; Dodge RK; Schell WA
Antimicrob Agents Chemother; 1996 Aug; 40(8):1910-3. PubMed ID: 8843302
[TBL] [Abstract][Full Text] [Related]
13. Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates and clinical outcomes of cryptococcal meningitis in HIV-infected patients with/without fluconazole prophylaxis.
Manosuthi W; Sungkanuparph S; Thongyen S; Chumpathat N; Eampokalap B; Thawornwan U; Foongladda S
J Med Assoc Thai; 2006 Jun; 89(6):795-802. PubMed ID: 16850679
[TBL] [Abstract][Full Text] [Related]
14. Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: the role of antifungal susceptibility testing.
Witt MD; Lewis RJ; Larsen RA; Milefchik EN; Leal MA; Haubrich RH; Richie JA; Edwards JE; Ghannoum MA
Clin Infect Dis; 1996 Feb; 22(2):322-8. PubMed ID: 8838190
[TBL] [Abstract][Full Text] [Related]
15. A systematic review of fluconazole resistance in clinical isolates of Cryptococcus species.
Bongomin F; Oladele RO; Gago S; Moore CB; Richardson MD
Mycoses; 2018 May; 61(5):290-297. PubMed ID: 29377368
[TBL] [Abstract][Full Text] [Related]
16. A multi-arm, parallel, preclinical study investigating the potential benefits of acetazolamide, candesartan, and triciribine in combination with fluconazole for the treatment of cryptococcal meningoencephalitis.
Alanazi AH; Chastain DB; Rudraraju M; Parvathagiri V; Shan S; Lin X; Henao-Martínez AF; Franco-Paredes C; Narayanan SP; Somanath PR
Eur J Pharmacol; 2023 Dec; 960():176177. PubMed ID: 37931839
[TBL] [Abstract][Full Text] [Related]
17. Decreasing fluconazole susceptibility of clinical South African Cryptococcus neoformans isolates over a decade.
Naicker SD; Mpembe RS; Maphanga TG; Zulu TG; Desanto D; Wadula J; Mvelase N; Maluleka C; Reddy K; Dawood H; Maloba M; Govender NP;
PLoS Negl Trop Dis; 2020 Mar; 14(3):e0008137. PubMed ID: 32231354
[TBL] [Abstract][Full Text] [Related]
18. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing.
Pfaller MA; Diekema DJ; Sheehan DJ
Clin Microbiol Rev; 2006 Apr; 19(2):435-47. PubMed ID: 16614256
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamics of ATI-2307 in a rabbit model of cryptococcal meningoencephalitis.
Giamberardino CD; Tenor JL; Toffaletti DL; Palmucci JR; Schell W; Boua J-VK; Marius C; Stott KE; Steele SL; Hope W; Cilla D; Perfect JR
Antimicrob Agents Chemother; 2023 Oct; 67(10):e0081823. PubMed ID: 37728934
[TBL] [Abstract][Full Text] [Related]
20. Correlation of anti-fungal susceptibility with clinical outcomes in patients with cryptococcal meningitis.
Lee CH; Chang TY; Liu JW; Chen FJ; Chien CC; Tang YF; Lu CH
BMC Infect Dis; 2012 Dec; 12():361. PubMed ID: 23253817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
